Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.

Consistent with the findings of a previous study involving a non-Asian, Western population, our study suggested that baseline ALC may be a predictive factor for the survival benefit of eribulin in Japanese patients.